Form 4: PTC Therapeutics Officer Sells Shares for Tax Obligations
Insider Transaction Report
A PTC Therapeutics officer sold shares to cover tax withholding obligations related to vested restricted stock units.
Summary
- Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics, Inc. (PTCT), reported sales of common stock.
- The transactions occurred on January 6, 2026, and January 7, 2026.
- On January 6, 2026, 1,279 shares were sold directly at $76.95 per share, and 54 shares were sold indirectly by spouse at $76.95 per share.
- On January 7, 2026, 1,026 shares were sold directly at $77.48 per share, and 52 shares were sold indirectly by spouse at $77.48 per share.
- These sales were automatic, pursuant to an irrevocable 'sell to cover' election, to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).
- The vested RSUs included 4,750 and 178 units from a January 3, 2025 grant, and 4,250 and 177 units from a January 5, 2023 grant.
- Following these transactions, Mr. Almstead beneficially owns 116,077 shares directly and 6,850 shares indirectly by spouse.
Sentiment
Score: 5
Explanation: The filing reports routine, non-discretionary sales of shares to cover tax withholding obligations upon RSU vesting, which is a neutral event for market sentiment.
Future Outlook
No forward-looking statements or guidance are provided in this Form 4 filing.
Industry Context
This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders: Minimal impact, as these are routine, non-discretionary sales for tax purposes and do not reflect a change in the officer's discretionary investment decision or company outlook.
Key Dates
| Date | Description |
|---|---|
| 01/05/2023 | Grant date for 17,000 and 710 Restricted Stock Units (RSUs). |
| 01/03/2025 | Grant date for 19,000 and 715 Restricted Stock Units (RSUs). |
| 01/06/2026 | Transaction date for the sale of 1,279 direct shares and 54 indirect shares. |
| 01/07/2026 | Transaction date for the sale of 1,026 direct shares and 52 indirect shares. |
| 01/08/2026 | Signature date of the reporting person's attorney-in-fact. |
Recommendation
holdThe filing details routine, non-discretionary sales by an officer to cover tax obligations upon the vesting of restricted stock units. This type of transaction is a standard part of equity compensation plans and does not reflect a discretionary decision by the insider to sell shares based on company performance or outlook. Therefore, it provides no new information to alter an investment thesis, warranting a 'hold' recommendation based solely on this filing.
Keywords
PTC Therapeutics, PTCT, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Equity Compensation, Tax Withholding, Officer Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.